Description

Data from the placebo group of the 4D study. This study aimed at comparing atorvastatin to placebo for patients with type 2 diabetes and receiving hemodialysis in terms of cariovascular events. The primary endpoint was a composite of death from cardiac causes, stroke and non-fatal myocardial infarction. Competing event was death from other causes.

Usage

Format

A data frame with 636 observations on the following 7 variables.

id

Patients' id number

sex

Patients' gender

age

Patients' age

medication

Character vector indicating treatment affiliation. Here only equal to "Placebo"

status

Status at the end of the follow-up. 1 for the event of interest, 2 for death from other causes and 0 for censored observations

time

Survival time

treated

Numeric vector indicated whether patients are treated or not. Here always equal to zero

Source

Wanner, C., Krane, V., Maerz, W., Olschewski, M., Mann, J., Ruf, G., Ritz, E (2005). Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New England Journal of Medicine, 353(3), 238–248.

References

Allignol, A., Schumacher, M., Wanner, C., Dreschler, C. and Beyersmann, J. (2010). Understanding competing risks: a simulation point of view. Research report.

Examples